Health News Releases

  • Today April 30
February 27, 14:30
Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acqui
February 25, 15:58
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics
Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane prod
Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies
February 24, 16:26
Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies
Angelini Pharma (https://www.angelinipharma.com/), part of the privately owned Angelini Industries, and Quiver Bioscience (https://www.quiverbioscience.com/) (“Quiver”), a discovery technology and the
February 24, 16:10
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to exclusi
Rare Diseases: Collaboration is key. image: AdobeStock_1308212316
February 24, 10:15
AOP Health on Rare Diseases: Information. Collaboration. Innovation.
Between 27 and 36 million[1] people in Europe are living with a rare disease, yet only around six percent currently have access to an approved treatment[2]. Progress in diagnosis and treatment is ofte
February 22, 09:40
YolTech Therapeutics Announces Positive Interim Data on YOLT-202 for the Treatment of Alpha-1 Antitrypsin Deficiency
YolTech Therapeutics (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.yoltx.com%2F&esheet=54428688&newsitemid=20260219197004&lan=en-US&anchor=YolTech+Therapeutics&index=1&md5=5e9
February 20, 09:57
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54427813&newsitemid=20260218745615&lan=en-US&anchor=TSE%3A4
Michael Clay, Caidya's Chief Operating Officer
February 18, 13:05
Caidya Names Michael Clay COO to Drive Operational Excellence and Advance Multi-Regional Clinical Development
Caidya (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.caidya.com%2F&esheet=54426559&newsitemid=20260217431202&lan=en-US&anchor=Caidya&index=1&md5=7b2712d1d79f058b73bc0260a86357
February 18, 09:09
Galderma Announces Appointment of New Chief Financial Officer
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the appointment of Luigi La Corte as Chief Financial Officer (CFO), effective May 1, 2026. Luigi La Corte wi
February 13, 16:00
Angelalign Technology Inc. (6699.HK) Says a Preliminary European Court Ruling on Certain Software Features Will Have Minimal Impact on Users
Angelalign Technology Inc. (6699.HK) (“Angel”) said a ruling by the Unified Patent Court of Düsseldorf, Germany that it preliminarily cease its use of certain software functions that automatically upd
February 12, 15:22
We Are All Sculptra: First-of-its-Kind Galderma Initiative to Demonstrate How Everyone Can Benefit from Sculptra’s Regenerative Properties
Galderma (SIX: GALD), the pure-play dermatology category leader, today unveiled We Are All Sculptra, a unique program designed to capture the clinical impact of Sculptra® across nine diverse patients
February 11, 15:30
Kirin and Immunosens Launch Joint Development of a Self-Testing Service That Uses Urinary IgA to Visualize a Person’s Immune Status
Kirin Holdings Company, Limited (Kirin Holdings) and Immunosens Co., Ltd. (Immunosens) have begun the joint development of a unique “Self-Testing Service[1]” designed to visualize a person’s immune st
February 11, 15:13
Galderma Expands Restylane® Portfolio in Japan With Launch of OBT™ Hyaluronic Acid Injectables Restylane Defyne™ and Refyne™
Galderma (SIX: GALD), the pure-play dermatology category leader, has announced the launch of Restylane Defyne and Restylane Refyne: the first OBT based hyaluronic acid injectables ever authorized in J
February 10, 17:30
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54421686&newsitemid=20260210380286&lan=en-US&ancho
February 06, 15:50
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Grou
February 06, 11:40
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat® KMT2A + MRD Assay and Software to its industry-leading oncol
InterSystems earns four Best in KLAS awards for 2026
February 06, 10:50
InterSystems Honored with Four 2026 Best in KLAS Awards
InterSystems, a creative data technology provider powering more than one billion health records globally, today announced it has received four Global 2026 Best in KLAS awards. The company earned a #1
February 05, 13:40
China NMPA Approves Promega MSI Detection Kit as Companion Diagnostic for KEYTRUDA®
The National Medical Products Administration (NMPA) has approved the OncoMate® Microsatellite Instability (MSI) Detection Kit as a Class III in vitro diagnostic medical device in China. It is intended
Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibilit
February 02, 17:16
Aesthetic Brand Lorient Showcases K-Beauty Excellence at IMCAS World Congress 2026
Lorient, a premium aesthetic brand, announced that it has attracted global attention at the 27th IMCAS World Congress 2026 in Paris, garnering over 15,000 professionals and demonstrating its leadershi
February 02, 15:13
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission
Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and l
January 30, 15:34
Galderma Tackles Menopause-related Skin Changes With Global Survey and Clinical Trial Inclusivity
Galderma (SIX: GALD) has unveiled findings from a global survey of peri- and post-menopausal women from nine countries exploring the impact of menopause on the skin at the International Master Course
January 30, 10:50
Organon Completes Divestiture of JADA® System to Laborie
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today the successful closing of the sale of its JADA®
January 29, 15:52
Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead
Takeda (TOKYO:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54404180&newsitemid=20260128993781&lan=en-US&anc
January 29, 15:24
Galderma Unveils ‘Wake Up To Restylane’, Underscoring Restylane as the Ideal Hyaluronic Acid Treatment for Always-On Natural Beauty
Galderma (SIX: GALD), the pure-play dermatology category leader, has launched ‘Wake Up To Restylane’, a global campaign that showcases Restylane as an everyday beauty ally. Aligned with the growing de
January 29, 10:40
Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G pTau 217 CSF Assay for Research Use Only
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 CSF assay for the fully automated LUMIPULSE® G immunoassay analyzers. Th
25 per page50 per page75 per page100 per page